Cargando…
Cardiac complication after experimental human malaria infection: a case report
A 20 year-old healthy female volunteer participated in a clinical Phase I and IIa safety and efficacy trial with candidate malaria vaccine PfLSA-3-rec adjuvanted with aluminium hydroxide. Eleven weeks after the third and last immunization she was experimentally infected by bites of Plasmodium falcip...
Autores principales: | Nieman, An-Emmie, de Mast, Quirijn, Roestenberg, Meta, Wiersma, Jorien, Pop, Gheorghe, Stalenhoef, Anton, Druilhe, Pierre, Sauerwein, Robert, van der Ven, André |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2009
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2794284/ https://www.ncbi.nlm.nih.gov/pubmed/19958549 http://dx.doi.org/10.1186/1475-2875-8-277 |
Ejemplares similares
-
Longevity and Composition of Cellular Immune Responses Following Experimental Plasmodium falciparum Malaria Infection in Humans
por: Teirlinck, Anne C., et al.
Publicado: (2011) -
Idiopathic acute myocarditis during treatment for controlled human malaria infection: a case report
por: van Meer, Maurits PA, et al.
Publicado: (2014) -
Safety and Immunogenicity of a Recombinant Plasmodium falciparum AMA1 Malaria Vaccine Adjuvanted with Alhydrogel™, Montanide ISA 720 or AS02
por: Roestenberg, Meta, et al.
Publicado: (2008) -
Comparison of Clinical and Parasitological Data from Controlled Human Malaria Infection Trials
por: Roestenberg, Meta, et al.
Publicado: (2012) -
The XN-30 hematology analyzer for rapid sensitive detection of malaria: a diagnostic accuracy study
por: Post, Annelies, et al.
Publicado: (2019)